Schott, G., Pachl, H., Limbach, U., Gundert-Remy, U., Ludwig, W.D. and Lieb, K. (2010) The financing of drug trials by pharmaceutical companies and its consequences. Part 2: A qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Deutsches Aerzteblatt International (German), 107, 295-301.

has been cited by the following article:

• TITLE: Sponsor-investigator-relationship: challenges, recent regulatory developments and future legislative trends

  AUTHORS: Raphael Richard Ciuman

  KEYWORDS: Investigator; Sponsor; Clinical Trial; Non-Commercial Trial; European Clinical Trials Directive; Conflict of Interest

  JOURNAL NAME: Health, Vol.3 No.12, December 8, 2011

  ABSTRACT: Correct definition and management of sponsor- investigator relationship is of central importance for planing and executing clinical trials. During the last decade, there have been numerous modifications of guidelindes, international and national legislations and regulations. This implicated various alterations and shifts of essential responsibilities and tasks relating to the investigator, sponsor or sponsor-investigator what raised financial, clinical and ethical issues. First experiences with these new regulations and legislations are discussed together with international differences and their impacts on clinical trials. Regarding non-commercial trials and institutional sponsorship, there are still open organizational and legal questions after national implementation of the Europeam Clinical Trials Directive in 2004, although various approaches have been suggested in recent years in Europe. Current trends and controversies are discussed as well. A literature review was performed summarizing recent experiences with current legislations and risen controversies of these new legislations showing impact on future trends.